Marco Mazzotta
UOC Oncologia Interpresidio ASL Roma 2 · ASL Roma 2 - Ospedale Sandro Pertini & Ospedale Sant'Eugenio
https://researchid.co/marcomazzotta88
@aslroma2.it
65Scopus Publications
1680Google Scholar Citations
21Google Scholar h-index
42Google Scholar i10-index
Recent Scopus Publications
- Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER study
- Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2− breast cancer patients with bone metastases
- Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study
- Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors
- Tolerability and Preliminary Outcomes of Adjuvant T-DM1 in HER2-Positive Breast Cancer After Neoadjuvant Therapy: The ATD Study
Links
- ORCID https://orcid.org/0000-0002-5478-9831
- Google Scholar https://scholar.google.com/citations?user=0cJSzjgAAAAJ
- Scopus https://www.scopus.com/authid/detail.uri?authorId=57193025703